Merck brings customers closer to gene therapy product commercialization

Merck today announced that its Carlsbad, California-based manufacturing facility for the production of BioReliance® viral and gene therapy products has completed both a U.S. Food & Drug Administration (FDA) Pre-License inspection and a European Medicines Agency (EMA) Marketing Authorization Application inspection.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news